Report post

Are CSL Behring shares undervalued?

The guidance factors in continued gross margin recovery in CSL Behring and constant-currency group revenue growth of 9%-11%, largely driven by immunoglobulins, or Ig. We keep our estimates broadly unchanged and maintain our AUD 310 fair value estimate. Shares remain slightly undervalued. CSL is trading at a 791% premium.

What is CSL Behring & Seqirus?

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015.

Is CSL Ltd a government company?

Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe. See the latest CSL Ltd stock price (CSL:XASX), related news, valuation, dividends and more to help you make your investing decisions.

The World's Leading Crypto Trading Platform

Get my welcome gifts